News
Myeloid Therapeutics to Participate at SVB Securities Biopharma Company Connect Event

CAMBRIDGE, Mass., May 23, 2023 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today announced that it will participate in the SVB Securities Biopharma Company Connect event, taking place virtually May 24th– 25th, 2023.
Myeloid management will participate in virtual one-on-one meetings with investors during the event.
About Myeloid Therapeutics
Myeloid Therapeutics is a clinical stage mRNA-immunotherapy company developing novel therapies for cancer. Integrating the fields of RNA, immunology and medicine, the Company’s proprietary platform provides clinical solutions by matching therapeutic modalities to disease conditions, including use of autologous cell therapies, in vivo cell programming using mRNA, and RNA-based gene-editing using RetroT™.
Investor and Media Contact
Amy Conrad
Juniper Point
[email protected]
858-914-1962
SOURCE Myeloid
-
Health7 months ago
Alan Thicke’s Intriguing Contribution To Juvenile Diabetes, Because His Legacy Lives On
-
Health7 months ago
Prevention And Treatment Of Opportunistic Infections In HIV
-
Health7 months ago
RSV Experimental Vaccine For Children- Risks And Consequences
-
Health7 months ago
Combat Stress: Effective Strategies And Resources For Managing Your Stress!
-
Health7 months ago
Reasons Why Your Pet Is The Perfect Workout Partner!
-
Uncategorized6 years ago
These ’90s fashion trends are making a comeback in 2017
-
Trending5 months ago
Belle Delphine: All About The Bathwater Gamer Girl!
-
News5 months ago
Patti LaBelle Concert Evacuated Due To A Bomb Threat